Sector ratings Monte Rosa Therapeutics, Inc.

Stocks

Market Closed - Nasdaq 21:00:00 04/09/2026 BST			5-day change	1st Jan Change
13.84 ^USD	-3.76%		+3.44%	-11.73%

08-24	Monte Rosa Therapeutics Doses First Patient in Phase 2 Prostate Cancer Study	MT
08-24	Monte Rosa Therapeutics Doses First Patient In MODeFIRe-1 Phase 2 Study Of MRT-2359 In Combination With Apalutamide In Patients With AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer	CI

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Global Valuation
MONTE ROSA THERAPEUTICS, INC.	1.18B	-	BB	-	-
LONZA GROUP AG	48.93B		AAA
REVOLUTION MEDICINES, INC.	45.01B	-	B	-	-
IQVIA HOLDINGS INC.	44.07B		AAA
BEONE MEDICINES AG	40.73B		-
CELLTRION, INC.	33.52B		A
ASCENDIS PHARMA A/S	17.77B	-	-	-	-
MEDPACE HOLDINGS, INC.	16.5B		BBB
EUROFINS SCIENTIFIC SE	14.67B		AA
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	13.77B		AA
ICON PUBLIC LIMITED COMPANY	12.72B		AAA
TEMPUS AI, INC.	11.66B		A		-
BIO-TECHNE CORPORATION	11.36B		AA
PHARMARON BEIJING CO., LTD.	10.39B		AA
ABIVAX	10.61B	-	BBB	-	-
GENSCRIPT BIOTECH CORPORATION	8.77B		AA		-
PRAXIS PRECISION MEDICINES, INC.	9.82B	-	B	-	-
KYMERA THERAPEUTICS, INC.	9.76B	-	BBB	-	-
IONIS PHARMACEUTICALS, INC.	9.65B	-	A	-	-
PROTAGONIST THERAPEUTICS, INC.	9.43B		BB		-
Average	19.02B		A
Weighted average by Cap.			A